Literature DB >> 31642613

Prediction of a miRNA-mRNA functional synergistic network for cervical squamous cell carcinoma.

Dan Sun1, Lu Han1, Rui Cao1, Huali Wang1, Jiyong Jiang1, Yanjie Deng1, Xiaohui Yu1.   

Abstract

Cervical squamous cell carcinoma (CSCC) accounts for a significant proportion of cervical cancer; thus, there is a need for novel and noninvasive diagnostic biomarkers for this malignancy. In this study, we performed integrated analysis of a dataset from the Gene Expression Omnibus database to identify differentially expressed genes (DEGs) and differentially expressed miRNAs (DEmiRNAs) between CSCC, cervical intraepithelial neoplasia (CIN) and healthy control subjects. We further established protein-protein interaction and DEmiRNA-target gene interaction networks, and performed functional annotation of the target genes of DEmiRNAs. In total, we identified 1375 DEGs and 19 DEmiRNAs in CIN versus normal control, and 2235 DEGs and 33 DEmiRNAs in CSCC versus CIN by integrated analysis. Our protein-protein interaction network indicates that the common DEGs, Cyclin B/cyclin-dependent kinase 1 (CDK1), CCND1, ESR1 and Aurora kinase A (AURKA), are the top four hub genes. P53 and prostate cancer were identified as significantly enriched signaling pathways of common DEGs and DEmiRNA targets, respectively. We validated that expression levels of three DEGs (TYMS, SASH1 and CDK1) and one DEmiRNA of hsa-miR-99a were altered in blood samples of patients with CSCC. In conclusion, a total of four DEGs (TYMS, SASH1, CDK1 and AURKA) and two DEmiRNAs (hsa-miR-21 and hsa-miR-99a) may be involved in the pathogenesis of CIN and the progression of CIN into CSCC. Of these, TYMS is predicted to be regulated by hsa-miR-99a and SASH1 to be regulated by hsa-miR-21.
© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

Entities:  

Keywords:  GEO; cervical intraepithelial neoplasia; cervical squamous cell carcinoma; differentially expressed gene; miRNA

Year:  2019        PMID: 31642613      PMCID: PMC6886301          DOI: 10.1002/2211-5463.12747

Source DB:  PubMed          Journal:  FEBS Open Bio        ISSN: 2211-5463            Impact factor:   2.693


cervical intraepithelial neoplasia cervical squamous cell carcinoma differentially expressed gene differentially expressed miRNA false discovery rate Gene Expression Omnibus gene ontology Kyoto Encyclopedia of Genes and Genomes normal control protein‐protein interaction Cervical carcinoma is one of the leading causes of cancer‐related mortality in the world and accounts for 10–15% of tumor‐related deaths in women 1. Recently, the occurrence rate of cervical cancer is higher in younger women 2. Because of the progression in screening methods, more and more patients are diagnosed with cervical cancer at the early stage 3. Cervical intraepithelial neoplasia (CIN) is a class of precancerous lesions of cervical squamous cell carcinoma (CSCC). CIN can be categorized as CIN I, CIN II or CIN III. The risk of CIN I, CIN II and CIN II developing into cervical cancer was 1%, 5% and 12–22%, respectively. The possibility of CIN evolving into cervical carcinoma is 20‐fold higher than that of a normal cervix 4. Thus, the cure of CIN plays a key role in the prevention of cervical cancer. Up to now, the mechanism underlying the progression of CIN into CSCC remains poorly elucidated. Therefore, it is imperative to find diagnostic biomarkers that can contribute to exploring the mechanism in progression of CIN developing into CSCC. miRNAs are a group of small, noncoding RNAs of 20–22 nucleotides that modulate about 60% of protein‐coding genes 5. miRNAs may play a key role in novel diagnostic, prognostic and therapeutic markers in clinical oncology. In addition, no curative therapy can be used for CSCC, and the current methods have only limited efficacy. Therefore, it is essential to identify accurate and credible biomarkers for CSCC diagnosis and treatment. In our study, we intended to obtain more credible results than possible with individual study via integrated analysis. We performed functional annotation of differentially expressed genes (DEGs) and a CSCC‐specific miRNA‐target gene network to seek key DEGs and differentially expressed miRNAs (DEmiRNAs) in CIN and biomarkers in the development of CIN into CSCC.

Materials and methods

DEGs identification of CSCC and CIN

We searched gene expression datasets of CSCC and CIN from the Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo) 6. Search keywords were [‘cervical intraepithelial neoplasia’ (MeSH Terms) OR cervical intraepithelial neoplasia (All Fields)] OR {[‘cervical’ (MeSH Terms) OR cervical (All Fields)] AND [‘carcinoma’ (MeSH Terms) OR carcinoma (All Fields)]} AND ‘gse’ (Filter) 7. The study types were limited to ‘expression profiling by array’. Datasets that meet the following criteria would be included in our study: (a) the selected dataset must be genome‐wide mRNA or miRNA transcriptome data; (b) these data were obtained from tissues of the CIN, CSCC and normal control (N) (no drug stimulation or transfection); and (c) normalized or raw datasets were considered in this study. Finally, three datasets of mRNA and miRNA were screened and included. The study methodologies conformed to the standards set by the Declaration of Helsinki.

Identification of DEGs and DEmiRNAs in CIN versus N and CIN versus CSCC

The method used for P‐value consolidation is the inverse normal method in the limma package and metaMA 8. The adopted standard is false discovery rate (FDR) < 0.05, and all datasets have the same direction of different expression. Finally, the DEGs and DEmiRNAs of CIN versus N and CIN versus CSCC were obtained. Intersection of DEGs and DEmiRNAs was obtained from CIN versus N and CSCC versus CIN.

Gene ontology and pathway enrichment analysis of DEGs

To identify the characteristic biological function and potential pathways of common DEGs, we performed gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment by using the online software genecodis3 9. All common DEGs were analyzed by GO and KEGG enrichment analysis using the r language (GSEABase package).

Protein‐protein interaction network construction of common DEGs

Cytoscape 3.5.0 was used to search for all common DEGs based on the existing data of protein interaction in the String database. All common DEGs in CIN versus N and CIN versus CSCC groups were used to construct the protein‐protein interaction (PPI) network 10, 11, 12.

DEmiRNA‐target interaction network in CIN versus N and CIN versus CSCC

miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/php/index.php) 13 provides the latest and extensive experimentally validated miRNA‐target interaction information. The potential target genes of miRNAs were predicted by miRTarBase, which is an experimentally validated miRNA‐target interactions database in CIN versus N and CIN versus CSCC, respectively.

Functional annotation of target mRNAs

Based on the earlier analysis results, we obtained seven target genes of DEmiRNAs. GO functional enrichment and KEGG functional enrichment analysis were performed on target genes using genecodis3 (http://genecodis.cnb.csic.es/analysis). FDR < 0.05 was defined as the criterion of statistical significance.

Quantitative RT‐PCR confirmation

According to the results of GEO integrated analysis, we selected two DEmiRNAs (hsa‐miR‐99a and hsa‐miR‐21) and three targets including TYMS, SASH1 and Aurora kinase A (AURKA) in CIN versus CSCC as candidate genes. A total of 12 blood samples were collected from four N subjects, four patients diagnosed with CIN and four patients diagnosed with CSCC. Informed written consent was obtained from all participants, and research protocols were approved by the Ethics Committee of our hospital.

Results

Differential expression analysis of genes in CIN and CSCC

After retrieving, we obtained three microarray studies of mRNA and three microarray studies of miRNA according to the inclusion criteria from the GEO database. The characteristics of the individual database for the integrated analysis are displayed in Table 1.
Table 1

mRNA and miRNA expression datasets used in this study.

GEO IDAuthorPlatformSamples (N : CIN : CESC)Year
mRNA
GSE63514 den Boon JGPL570 [HG‐U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array24 : 76 : 282015
GSE51993 Mo WGPL10558 Illumina Human HT‐12 V4.0 expression bead chip7 : 17 : 02013
GSE7803 Kuick RGPL96 [HG‐U133A] Affymetrix Human Genome U133A Array10 : 7 : 212007
miRNA
GSE30656 Sie DGPL6955 Agilent‐016436 Human miRNA Microarray 1.0 (Feature Number version)10 : 18 : 102012
GSE46172 Mo WGPL8179 Illumina Human v2 MicroRNA expression bead chip7 : 17 : 02013
GSE19611 Pereira PMGPL7534 National DNA microarray facility of University of Aveiro miRNA chip v1.123 : 16 : 42010
mRNA and miRNA expression datasets used in this study. A total of 1375 DEGs were obtained with FDR < 0.05 in CIN compared with N, among which the expression level of 719 genes was increased and the expression level of 656 genes was decreased. Likewise, 2235 DEGs with 1213 up‐regulated and 1022 down‐regulated genes were obtained in CSCC compared with CIN. The top 20 DEGs in CIN versus N and CESC versus CIN are listed in Tables 2 and 3, respectively. The hierarchical clustering heatmap of the top 100 most significantly up‐regulated or down‐regulated genes in CIN versus N and CSCC versus CIN is shown in Fig. 1A,B. In total, 392 common DEGs were obtained by taking the intersection of CIN versus N and CSCC versus CIN (Fig. 1C).
Table 2

Most differentially expressed mRNAs in CIN versus N. Combined.ES, Combined Effect Size.

IDSymbolCombined.ES P‐valueFDRUp‐regulated or down‐regulated
4175 MCM6 1.63E+006.13E−147.02E−10Up
6491 STIL 1.58E+001.24E−137.02E−10Up
51514 DTL 1.61E+001.72E−137.02E−10Up
2237 FEN1 1.52E+005.16E−131.58E−9Up
8317CDC71.58E+006.88E−131.68E−9Up
4751 NEK2 1.50E+008.36E−131.71E−9Up
5985 RFC5 1.49E+001.24E−122.17E−9Up
1029 CDKN2A 1.50E+001.42E−122.17E−9Up
10635 RAD51AP1 1.49E+002.18E−122.97E−9Up
79022 TMEM106C 1.44E+003.50E−123.92E−9Up
10493 VAT1 −1.31E+004.05E−101.15E−7Down
2012 EMP1 −1.30E+005.22E−101.42E−7Down
794 CALB2 −1.26E+001.10E−92.63E−7Down
51754 TMEM8B −1.24E+001.53E−93.38E−7Down
79919 C2orf54 −1.23E+005.66E−98.77E−7Down
23136 EPB41L3 −1.17E+007.59E−91.12E−6Down
9846 GAB2 −1.17E+009.56E−91.36E−6Down
10749 KIF1C −1.15E+001.85E−82.36E−6Down
5630 PRPH −1.11E+003.33E−83.74E−6Down
9778 KIAA0232 −1.13E+003.49E−83.85E−6Down
Table 3

Most differentially expressed mRNAs in CESC versus CIN. Combined.ES, Combined Effect Size.

IDSymbolCombined.ES P‐valueFDRUp‐regulated or down‐regulated
7130 TNFAIP6 1.81E+008.88E−162.72E−12Up
26585 GREM1 1.70E+003.57E−145.47E−11Up
23350 U2SURP 1.67E+001.90E−132.12E−10Up
10299 6‐Mar 1.57E+005.98E−134.88E−10Up
6574 SLC20A1 1.55E+007.90E−136.04E−10Up
87 ACTN1 1.46E+001.00E−115.12E−9Up
5352 PLOD2 1.49E+001.20E−115.85E−9Up
10721 POLQ 1.49E+003.02E−111.06E−8Up
3836 KPNA1 1.40E+004.24E−111.27E−8Up
9532 BAG2 1.44E+004.67E−111.36E−8Up
8857 FCGBP −2.26E+0000Down
6338 SCNN1B −1.96E+0000Down
49860 CRNN −1.81E+006.66E−162.72E−12Down
4013 VWA5A −1.74E+008.22E−152.01E−11Down
22802 CLCA4 −1.70E+001.64E−143.03E−11Down
11005 SPINK5 −1.69E+001.73E−143.03E−11Down
7263 TST −1.65E+005.26E−146.50E−11Down
6947 TCN1 −1.68E+005.31E−146.50E−11Down
51090 PLLP −1.60E+002.09E−132.13E−10Down
6590 SLPI −1.59E+002.73E−132.57E−10Down
Figure 1

Heatmap image showing the DEGs that were significantly up‐regulated or down‐regulated (FDR < 0.05) in CIN versus N and CIN versus CSCC. (A) The top 100 most significantly up‐regulated and down‐regulated genes in CIN versus N. (B) The top 100 most significantly up‐regulated and down‐regulated genes in CSCC versus CIN. (C) Common DEGs in CIN versus N and CSCC versus CIN. (D) The top 100 most significantly up‐regulated and down‐regulated miRNAs in CIN versus N. (E) The top 100 most significantly up‐regulated and down‐regulated miRNAs in CSCC versus CIN. (F) Common DEmiRNAs in CIN versus N and CSCC versus CIN.

Most differentially expressed mRNAs in CIN versus N. Combined.ES, Combined Effect Size. Most differentially expressed mRNAs in CESC versus CIN. Combined.ES, Combined Effect Size. Heatmap image showing the DEGs that were significantly up‐regulated or down‐regulated (FDR < 0.05) in CIN versus N and CIN versus CSCC. (A) The top 100 most significantly up‐regulated and down‐regulated genes in CIN versus N. (B) The top 100 most significantly up‐regulated and down‐regulated genes in CSCC versus CIN. (C) Common DEGs in CIN versus N and CSCC versus CIN. (D) The top 100 most significantly up‐regulated and down‐regulated miRNAs in CIN versus N. (E) The top 100 most significantly up‐regulated and down‐regulated miRNAs in CSCC versus CIN. (F) Common DEmiRNAs in CIN versus N and CSCC versus CIN. Nineteen DEmiRNAs (7 up‐regulated DEmiRNAs and 12 down‐regulated DEmiRNAs) were obtained with P < 0.05 in CIN compared with N. Likewise, 33 DEmiRNAs with 18 up‐regulated and 15 down‐regulated genes were obtained in CSCC compared with CIN. The top 20 DEmiRNAs in CIN versus N and CESC versus CIN are listed in Tables 4 and 5, respectively. The hierarchical clustering heatmap of DEmiRNAs is shown in Fig. 1D,E. A total of six common DEmiRNAs were obtained by taking the intersection of CIN versus N and CSCC versus CIN (Fig. 1F).
Table 4

DEmiRNAs in CIN versus N. Combined.ES, Combined Effect Size.

SymbolCombined.ES P‐valueFDRUp‐regulated or down‐regulated
hsa‐miR‐146a7.82E−16.53E−42.84E−2Up
hsa‐miR‐10a7.63E−17.03E−42.84E−2Up
hsa‐miR‐34b6.76E−12.69E−33.83E−2Up
hsa‐miR‐135b6.26E−16.00E−36.06E−2Up
hsa‐let‐7g4.74E−13.71E−22.01E−1Up
hsa‐miR‐254.54E−13.75E−22.01E−1Up
hsa‐miR‐214.69E−14.10E−22.01E−1Up
hsa‐miR‐203−1.25E+003.35E−74.05E−5Down
hsa‐miR‐149−7.73E−11.60E−33.51E−2Down
hsa‐miR‐210−7.00E−12.88E−33.83E−2Down
hsa‐miR‐23b−6.61E−13.17E−33.83E−2Down
hsa‐miR‐324‐3p−6.14E−16.01E−36.06E−2Down
hsa‐miR‐222−5.88E−18.09E−37.33E−2Down
hsa‐miR‐205−5.47E−11.25E−29.81E−2Down
hsa‐miR‐99a−5.41E−11.40E−29.97E−2Down
hsa‐miR‐24−4.98E−12.24E−21.51E−1Down
hsa‐miR‐30d−4.75E−12.96E−21.88E−1Down
hsa‐miR‐519d−4.58E−13.83E−22.01E−1Down
hsa‐miR‐214−4.27E−15.00E−22.24E−1Down
Table 5

DEmiRNAs in CESC versus CIN. Combined.ES, Combined Effect Size.

SymbolCombined.ES P‐valueFDRUp‐regulated or down‐regulated
hsa‐miR‐161.15E+006.06E−42.31E−2Up
hsa‐miR‐18a1.13E+007.63E−42.31E−2Up
hsa‐miR‐106a1.01E+002.51E−34.34E−2Up
hsa‐miR‐1859.49E−13.84E−34.65E−2Up
hsa‐miR‐200c9.20E−15.42E−35.97E−2Up
hsa‐miR‐318.72E−17.42E−37.45E−2Up
hsa‐miR‐939.02E−18.00E−37.45E−2Up
hsa‐miR‐106b8.24E−11.09E−28.07E−2Up
hsa‐miR‐98.06E−11.25E−28.07E−2Up
hsa‐miR‐2058.52E−11.38E−28.07E−2Up
hsa‐miR‐125b−1.52E+002.43E−52.94E−3Down
hsa‐miR‐195−1.31E+001.85E−41.12E−2Down
hsa‐miR‐29a−1.08E+001.42E−33.24E−2Down
hsa‐miR‐99a−1.05E+001.60E−33.24E−2Down
hsa‐miR‐497−9.61E−13.43E−34.65E−2Down
hsa‐miR‐29c−8.50E−18.82E−37.63E−2Down
hsa‐miR‐100−8.24E−11.10E−28.07E−2Down
hsa‐let‐7c−8.02E−11.32E−28.07E−2Down
hsa‐miR‐145−8.00E−11.36E−28.07E−2Down
hsa‐miR‐26a−7.79E−11.61E−28.10E−2Down
DEmiRNAs in CIN versus N. Combined.ES, Combined Effect Size. DEmiRNAs in CESC versus CIN. Combined.ES, Combined Effect Size.

Functional annotation of common DEGs

Functional annotation analysis manifested that these common DEGs were significantly involved in the mitotic cell cycle (FDR = 1.21E−27), cell division (FDR = 5.43E−22), protein binding (FDR = 9.90E−27), ATP binding (FDR = 7.68E−14), p53 signaling pathway (FDR = 0.0003714), cell cycle (FDR = 1.31E−9) and DNA replication (FDR = 7.79E−6) (Fig. 2). Details of all GO and KEGG items are listed in Table S1.
Figure 2

The top 15 most significantly enriched GO terms and KEGG pathways of common DEGs in CIN versus N and CSCC versus CIN. (A) The top 15 most significantly enriched GO terms of the biological process. (B) The top 15 most significantly enriched GO terms of the cellular component. (C) The top 15 most significantly enriched GO terms of molecular function. (D) The top 15 most significantly enriched KEGG pathways.

The top 15 most significantly enriched GO terms and KEGG pathways of common DEGs in CIN versus N and CSCC versus CIN. (A) The top 15 most significantly enriched GO terms of the biological process. (B) The top 15 most significantly enriched GO terms of the cellular component. (C) The top 15 most significantly enriched GO terms of molecular function. (D) The top 15 most significantly enriched KEGG pathways.

PPI network and module analysis of common DEGs

To identify potential interactions between common DEGs, we constructed a PPI network. In total, 259 nodes (genes) and 886 edges were identified among DEGs in the results, which are shown in Fig. 3. Among them, the higher degree genes are CDK1 (degree = 70), CCND1 (degree = 32), ESR1 (degree = 31), AURKA (degree = 30), BIRC5 (degree = 30), MAD2L1 (degree = 28), BUB1 (degree = 26), CDC6 (degree = 26), CENPE (degree = 26) and UMPS (degree = 26). The expression levels of these genes in three databases are shown in Fig. 4.
Figure 3

PPI network of common DEGs. Pink and aqua ellipses represent proteins encoded by up‐regulated and down‐regulated common DEGs, respectively. Purple ellipses indicate proteins encoded by common DEGs that have inconsistent expression levels in CIN versus N and CSCC versus CIN.

Figure 4

The expression level of hub genes (CDK1, CCND1, ESR1, AURKA, BIRC5, MAD2L1, BUB1, CDC6, CENPE and UMPS) in (A) GSE7803, (B) GSE51993 and (C) GSE63514. *P < 0.05, **P < 0.01, ***P < 0.001; the statistical t‐test was used to determine significance.

PPI network of common DEGs. Pink and aqua ellipses represent proteins encoded by up‐regulated and down‐regulated common DEGs, respectively. Purple ellipses indicate proteins encoded by common DEGs that have inconsistent expression levels in CIN versus N and CSCC versus CIN. The expression level of hub genes (CDK1, CCND1, ESR1, AURKA, BIRC5, MAD2L1, BUB1, CDC6, CENPE and UMPS) in (A) GSE7803, (B) GSE51993 and (C) GSE63514. *P < 0.05, **P < 0.01, ***P < 0.001; the statistical t‐test was used to determine significance. In total, 393 DEmiRNA‐target interaction pairs were obtained. The DEmiRNA‐target regulatory network was constructed based on these DEmiRNA‐target interaction pairs, which consisted of 326 nodes and 393 edges (Fig. 5A). Based on the CIN‐specific DEmiRNA‐target interaction network, has‐miR‐24 (degree = 64), has‐miR‐149 (degree = 45) and has‐miR‐519d (degree = 38) were the top three DEmiRNAs that regulated most DEGs. All of these DEmiRNAs were down‐regulated in CIN based on the GEO database.
Figure 5

DEmiRNA‐mRNA interaction network. Green represents down‐regulation of miRNAs or targets; red represents the up‐regulation of miRNAs or targets. (A) CIN versus N. (B) CSCC versus CIN.

DEmiRNA‐mRNA interaction network. Green represents down‐regulation of miRNAs or targets; red represents the up‐regulation of miRNAs or targets. (A) CIN versus N. (B) CSCC versus CIN. Likewise, 1396 DEmiRNA‐target interaction pairs were obtained, which consisted of 828 nodes and 1396 edges (Fig. 5B). Based on the CIN‐specific DEmiRNA‐target interaction network, has‐miR‐26b (degree = 212), has‐miR‐16 (degree = 98) and has‐let‐7a (degree = 82) were the top three DEmiRNAs. All of these DEmiRNAs were down‐regulated in CIN based on the GEO database. Also, the intersection of seven DEmiRNA‐target pairs was obtained in the above two sections. Among them, two interaction pairs (hsa‐miR‐21‐SASH1 and hsa‐miR‐99a‐TYMS) were involved in CIN and the progression of CIN into CSCC (Fig. 6). Topological properties of the DEmiRNA‐mRNA interaction pair of CIN versus N and CESC versus CIN are shown in Tables S2 and S3, respectively.
Figure 6

Seven DEmiRNA‐mRNA interaction pairs that were intersected in both CIN versus N and CSCC versus CIN.

Seven DEmiRNA‐mRNA interaction pairs that were intersected in both CIN versus N and CSCC versus CIN.

Functional annotation of DEmiRNA targets

Figure 7, immortalization of host cell by virus (FDR = 0.00243696), dTMP biosynthetic process (FDR = 0.00243696), deoxyribonucleoside monophosphate biosynthetic process (FDR = 0.00243696), inhibin‐betaglycan‐ActRII complex (FDR = 0.00593324), fibroblast growth factor 2 binding (FDR = 0.00477304) and CD4 receptor binding (FDR = 0.00477304) were the most significantly enriched GO terms. Prostate cancer (FDR = 3.00E−3) and melanoma (FDR = 3.00E−3) were two significantly enriched pathways. Details of all GO and KEGG items are listed in Table S4, among which pathway enrichment analysis for TYMS, CDK1, AURKA and SASH1 was further performed in SMPDB, BIOCYC, KEGG and REACTOME databases, which is shown in Table 6.
Figure 7

The top 15 most significantly enriched GO terms and KEGG pathways of DEmiRNAs targets. (A) The top 15 most significantly enriched GO terms of the biological process. (B) The top 15 most significantly enriched GO terms of the cellular component. (C) The top 15 most significantly enriched GO terms of molecular function. (D) The top 15 most significantly enriched KEGG pathways.

Table 6

Pathway enrichment analysis for four DEGs in SMPDB, BIOCYC, KEGG and REACTOME databases. Combined.ES, Combined Effect Size.

DatabaseGene namePathway
SMPDB TYMS beta‐Ureidopropionase deficiency Dihydropyrimidinase deficiency MNGIE (mitochondrial neurogastrointestinal encephalopathy) UMP synthase deficiency (orotic aciduria)
CDK1
AURKA
SASH1
BIOCYC TYMS dTMP de novo biosynthesis (mitochondrial) Pyrimidine deoxyribonucleotides salvage Pyrimidine deoxyribonucleotides de novo biosynthesis Pyrimidine deoxyribonucleotides biosynthesis from CTP
CDK1
AURKA
SASH1
KEGG TYMS Thymidylate synthase
CDK1 Cyclin‐dependent kinase 1
AURKA Aurora kinase A
SASH1 SAM and SH3 domain containing 1
REACTOME TYMS Cell cycle (Homo sapiens)
CDK1 Cell cycle (Homo sapiens)
AURKA Gene expression (transcription) (Homo sapiens), metabolism of proteins (Homo sapiens)
SASH1
The top 15 most significantly enriched GO terms and KEGG pathways of DEmiRNAs targets. (A) The top 15 most significantly enriched GO terms of the biological process. (B) The top 15 most significantly enriched GO terms of the cellular component. (C) The top 15 most significantly enriched GO terms of molecular function. (D) The top 15 most significantly enriched KEGG pathways. Pathway enrichment analysis for four DEGs in SMPDB, BIOCYC, KEGG and REACTOME databases. Combined.ES, Combined Effect Size. To indicate the results of integrated analysis, we selected two DEmiRNAs (hsa‐miR‐99a and hsa‐miR‐21) and three target genes including TYMS, SASH1 and AURKA in CIN versus CSCC. Based on the results of quantitative RT‐PCR, the expression of hsa‐miR‐99a, hsa‐miR‐21, AURKA and SASH1 was down‐regulated, whereas the expression of TYMS was up‐regulated in CIN compared with CSCC. The expression of TYMS, SASH1 and hsa‐miR‐99a was consistent with the results of our integrated analysis (Fig. 8).
Figure 8

Quantitative RT‐PCR results of three DEGs (TYMS, SASH1 and AURKA) and two DEmiRNAs (hsa‐miR‐21 and hsa‐miR‐99a) in CIN versus N. The error bars indicate SD. The statistical test used to determine significance was one‐way ANOVA. All of the data had biological duplicates, and each gene had three duplicates. *SASH1 has significant difference.

Quantitative RT‐PCR results of three DEGs (TYMS, SASH1 and AURKA) and two DEmiRNAs (hsa‐miR‐21 and hsa‐miR‐99a) in CIN versus N. The error bars indicate SD. The statistical test used to determine significance was one‐way ANOVA. All of the data had biological duplicates, and each gene had three duplicates. *SASH1 has significant difference.

Discussion

CIN is a class of precancerous lesions of the CSCC, but the mechanisms of CIN developing into CSCC need to be elucidated more clearly 2. In this study, we obtained 1375 DEGs and 19 DEmiRNAs in tissues of patients with CIN compared with N. Likewise, there were 2235 DEGs and 33 DEmiRNAs in tissues of patients with CSCC compared with patients with CIN. A total of four DEGs (AURKA, SASH1, CDK1 and TYMS) under the regulation of two DEmiRNAs (hsa‐miR‐21 and hsa‐miR‐99a) were associated with CIN and CSCC. CDK1 and AURKA are two major hallmarks of both CIN versus N and CIN versus CSCC. CDK1 has more than 70 regulatory targets, which play a vital role in the control of the cell cycle. In transcription and cell‐cycle progression, various target substrates are directly phosphorylated by CDK1 in response to various stimuli 14. As previously described, many patients with cancers had aberrant activation of CDKs and their modulators. Abnormal cell proliferation and genomic instability were caused by dysregulation of CDKs 15. According to our integrated analysis, up‐regulated CDK1 was modulated by hsa‐miR‐205 and hsa‐miR‐24 in the tissues of CIN versus N and by hsa‐miR‐195 and hsa‐miR‐497 in CIN versus CSCC, which have the same pattern in a previous study 16. In the PPI analysis, CDK1 has the highest degree among the hub proteins. Also, CDK1 was enriched in the p53 signaling pathway in the KEGG analysis. Luo et al. 16 reported that CDK1 played a complicated role in regulating genetic networks involved in the progression of cervical cancer. Prognosis of advanced stage cervical cancer may be enhanced by new therapeutics targeting CDK1 or its related pathways. This was consistent with our results, which indicated that CDK1 might serve as a biomarker for CIN and the progression of CIN into CSCC. AURKA is a member of a family of mitotic serine/threonine kinases. During mitosis and meiosis, AURKA is correlated with crucial processes, whose appropriate function is integral for normal cell proliferation 17. The first study related to the family of kinases in tumorigenesis reported that Aurora A and B were overexpressed in primary breast and colon tumor samples. Emerging studies found that AURKA was amplified or overexpressed in other tumor types, such as pancreatic, ovarian and hepatocellular tumors 18, 19, 20. Nae‐Fang Twu et al. 21 have shown that expression of AURKA was significantly increased in carcinoma and CIN 3 compared with the normal cervix. In our study, AURKA was up‐regulated in CIN versus N and CIN versus CSCC, which showed the same pattern with the previous study 21. In the PPI analysis, AURKA was among the top four hub proteins. In the GO and KEGG analysis, AURKA was enriched in the items of mitotic cell cycle, cell division and oocyte meiosis. Recently, many studies reported that SASH1 played a crucial role in inhibiting various tumors. For example, He et al. 22 reported that the gene of SASH1 inhibited the metastatic progression of hepatocarcinoma cells via regulating the sonic hedgehog signaling pathway. Ren et al. 23 showed that up‐regulation of SASH1 inhibited proliferation and migration of ovarian carcinoma cells. In line with these studies, another study 24 showed that SASH1 was down‐regulated in cervical cancer, indicating that SASH1 might play a negative role in cervical cancer. Up‐regulated TYMS by hsa‐miR‐99a and down‐regulated SASH1 by hsa‐miR‐21 were detected in CIN versus N and CIN versus CSCC in our study, indicating its important role in CIN, and up‐regulated TYMS and down‐regulated SASH1 might serve as a biomarker for CIN and the progression of CIN into CSCC. In addition, the expression of these two DEmRNAs in CIN in our integrated analysis was consistent with our quantitative RT‐PCR results. Recently, miRNAs have been described as potential diagnostic or prognostic markers for many cancers and can function as neoteric targets for cancer therapies, including cervical cancer 25, 26. As previously reported, miR‐21‐5p was expressed abnormally in patients with CSCC 27. Likewise, other researchers have reported that miR‐21 influenced tumorigenesis in the cervical squamous cell and served as an oncology miRNA (oncomiRNA) in cervical cancer 28, 29, 30. Up‐regulated hsa‐miR‐21 was detected in our integrated analysis. There were 50 and 34 targets of hsa‐miR‐21 in the DEmiRNA‐target interaction network in CIN versus N and CIN versus CSCC, respectively. Many studies have indicated that miR‐99a is correlated with tumor pathogen 31, 32, 33. The miR‐99a is down‐regulated in human cancers, such as endometrioid endometrial carcinoma, suggesting that miR‐99a may inhibit tumor progression 34. However, the role of miR‐99a in cervical cancer still needs to be elucidated. A previous study provided evidence that miR‐99a was down‐regulated in cervical cancer tissues 35. Our results revealed that hsa‐miR‐99a was down‐regulated in CIN versus N and CIN versus CSCC. There were 7 and 12 targets of hsa‐miR‐99a in the DEmiRNA‐target interaction network in CIN versus N and CIN versus CSCC, respectively. In conclusion, four DEGs (TYMS, SASH1, CDK1 and AURKA) and two DEmiRNAs (hsa‐miR‐21 and hsa‐miR‐99a) may be involved in the pathogenesis of CIN and the progression of CIN into CSCC, which might contribute to developing novel diagnostic and therapeutic strategies for early‐stage CIN. Among them, TYMS was regulated by hsa‐miR‐99a and SASH1 was regulated by hsa‐miR‐21.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

DS and LH contributed to the conception of the study. RC and HW contributed the materials and performed the experiment. JJ and YD performed the data analyses. YD and XY contributed significantly in writing the manuscript. All authors read and approved the final manuscript. Table S1 . GO (biological process, cellular component and molecular function) and KEGG items of common DEGs. Click here for additional data file. Table S2. Topological properties of the DEmiRNA‐mRNA interaction pair of CIN versus N. Click here for additional data file. Table S3. Topological properties of the DEmiRNA‐mRNA interaction pair of CESC versus CIN. Click here for additional data file. Table S4 . GO (biological process, cellular component and molecular function) and KEGG items of DEmiRNA targets. Click here for additional data file.
  35 in total

Review 1.  Building protein-protein interaction networks with proteomics and informatics tools.

Authors:  Mihaela E Sardiu; Michael P Washburn
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

2.  MicroRNA expression in cervical cancer: Novel diagnostic and prognostic biomarkers.

Authors:  Chundi Gao; Chao Zhou; Jing Zhuang; Lijuan Liu; Cun Liu; Huayao Li; Gongxi Liu; Junyu Wei; Changgang Sun
Journal:  J Cell Biochem       Date:  2018-05-08       Impact factor: 4.429

3.  MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A.

Authors:  Hongzhen Qin; Wenfei Liu
Journal:  J Cell Physiol       Date:  2018-11-15       Impact factor: 6.384

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  The accuracy of the Papanicolaou smear in the screening and diagnostic settings.

Authors:  Marylou Cárdenas-Turanzas; Michele Follen; Graciela M Nogueras-Gonzalez; J L Benedet; J Robert Beck; Scott B Cantor
Journal:  J Low Genit Tract Dis       Date:  2008-10       Impact factor: 1.925

Review 6.  Aurora A, meiosis and mitosis.

Authors:  Richard Crane; Bedrick Gadea; Laurie Littlepage; Hua Wu; Joan V Ruderman
Journal:  Biol Cell       Date:  2004-04       Impact factor: 4.458

7.  MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells.

Authors:  Qing Yao; Hui Xu; Qian-Qian Zhang; Hui Zhou; Liang-Hu Qu
Journal:  Biochem Biophys Res Commun       Date:  2009-08-12       Impact factor: 3.575

8.  miR-99a and -99b inhibit cervical cancer cell proliferation and invasion by targeting mTOR signaling pathway.

Authors:  Li Wang; Lihua Chang; Zhaorong Li; Qing Gao; Dongge Cai; Yingfang Tian; Lingxia Zeng; Mu Li
Journal:  Med Oncol       Date:  2014-03-26       Impact factor: 3.064

9.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review.

Authors:  Marilena V Iorio; Carlo M Croce
Journal:  EMBO Mol Med       Date:  2017-06       Impact factor: 12.137

10.  GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics.

Authors:  Daniel Tabas-Madrid; Ruben Nogales-Cadenas; Alberto Pascual-Montano
Journal:  Nucleic Acids Res       Date:  2012-05-09       Impact factor: 16.971

View more
  3 in total

1.  miR-99a-5p inhibits glycolysis and induces cell apoptosis in cervical cancer by targeting RRAGD.

Authors:  Gang Wang; Yu Lu; Shi Di; Maohua Xie; Fang Jing; Xiaoyan Dai
Journal:  Oncol Lett       Date:  2022-05-27       Impact factor: 3.111

2.  Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for Cervical Cancer.

Authors:  Md Selim Reza; Md Harun-Or-Roshid; Md Ariful Islam; Md Alim Hossen; Md Tofazzal Hossain; Shengzhong Feng; Wenhui Xi; Md Nurul Haque Mollah; Yanjie Wei
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

3.  Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies.

Authors:  Md Selim Reza; Md Alim Hossen; Md Harun-Or-Roshid; Mst Ayesha Siddika; Md Hadiul Kabir; Md Nurul Haque Mollah
Journal:  Discov Oncol       Date:  2022-08-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.